Antibody therapeutics are becoming increasingly important for the treatment of many diseases, with the global market now worth more than $100bn.
But discovering game-changing medicines is not for the fainthearted. Although the stakes are high, the barriers to success are even higher.
One start-up hoping to beat the odds is DJS Antibodies, which makes antibodies to membrane-embedded receptors, specifically G protein-coupled receptors (GPCR’s).
